The Mayo Clinic, through the vehicle of the North Central Cancer Treatment Group (NCCTG), will serve as a primary research base for the 29 CCOPs with NCCTG affiliations providing both treatment and cancer control trials. We will also serve as a research base for cancer control and treatment protocol activity of non- CCOP members of the NCCTG. We will cooperate with our affiliated CCOPs and other members in conducting appropriate continuing education and workshops. The research base will provide training and active support for their data managers/research associates and oncology nurses. We will coordinate their multidisciplinary involvement in clinical cancer research protocols. By holding regular meetings of NCCTG members, we will facilitate the review of ongoing research, plan future research, and related professional activities. The research base will continue the rigid quality control procedures which have proved so successful in the past, and upgrade these procedures as indicated. We will constantly monitor CCOP performance not only by timely review of patient accrual, data sheets, pathology material, operative reports, and radiation therapy port films, but also by periodic, randomly scheduled monitoring site visits. The research base will work with investigators and members in preparing publications as well as presentations for national and regional meetings. We will make every effort to provide members with reasons to be proud of their participation in the National Cancer Program. Our focus over this grant period will be the further expansion of our cancer control efforts to include high priority symptoms adversely affecting completion of cancer treatment as well as survivorship quality. We will incorporate associated basic laboratory support, leading to scientifically rigorous translational research efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037404-25
Application #
7848125
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Kelaghan, Joseph
Project Start
1983-09-15
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
25
Fiscal Year
2010
Total Cost
$2,758,979
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Kottschade, Lisa; Novotny, Paul; Lyss, Alan et al. (2016) Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance). Support Care Cancer 24:2661-7
Miller, Robert C; Petereit, Daniel G; Sloan, Jeff A et al. (2016) N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys 95:1168-74
Zimmerman, Collin; Atherton, Pamela J; Pachman, Deirdre et al. (2016) MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer 24:1071-8
Atherton, Pamela J; Burger, Kelli N; Pederson, Levi D et al. (2016) Patient-reported outcomes questionnaire compliance in Cancer Cooperative Group Trials (Alliance N0992). Clin Trials 13:612-620
Tan, A D; Novotny, P J; Kaur, J S et al. (2016) QOL and Survival Comparisons by Race in Oncology Clinical Trials. J Cancer Clin Oncol 2:

Showing the most recent 10 out of 376 publications